Nasdaq
$12.43▼ 1.35%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.76BShares out 1.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 9.17After-hours26.09.18 05:554Ownership#●●●
Trevi Therapeutics, Inc.
Insider Michael Thomas Heffernan has filed a Form 4 report disclosing his beneficial ownership of Trevi Therapeutics, Inc. securities as of September 15, 2026.…more
$12.43-1.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.15After-hours26.09.16 05:42144Ownership
Trevi Therapeutics, Inc.
Michael Thomas Heffernan, an insider at Trevi Therapeutics, Inc., has filed an SEC Form 144 to report the proposed sale of company shares. This is a standard filing disclosing the insider's plan to dispose of securities.…more
$12.43-1.35%vs prev closeView filingShare - 8.6After-hours26.08.07 05:16S-8Offering
Trevi Therapeutics, Inc.
트레비 테라퓨틱스(Trevi Therapeutics)는 '개정 및 재작성된 2019 주식 인센티브 플랜'에 따라 800만 주의 보통주를 신규 등록했습니다. 이번 등록은 임직원 대상 주식 보상을 위한 것으로, 주당 17.97달러를 기준으로 총 1억 4,376만 달러 규모의 주식이 발행될 예정입니다.…more
$12.43-1.35%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 20:30#●●●#●●●
Trevi Therapeutics to Present Phase 2b Results at CHEST 2026
Trevi Therapeutics announced that results from its Phase 2b CORAL trial of nalbuphine ER for chronic cough in IPF patients will be presented at the CHEST 2026 Annual Meeting. The presentation will focus on patient-reported outcomes, highlighting the clinical progress of the investigational therapy.…more
$12.43-1.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.3Pre-market26.09.03 20:30
●●●●●●●● ●●●●● ●●●●●●
Trevi Therapeutics announced that its senior management will participate in several upcoming healthcare investor conferences throughout September. These appearances are intended for corporate updates and investor relations, with no new material business agreements announced.…more
$12.43-1.35%vs prev close - 8.26Pre-market26.08.26 20:30
●●●●●●●● ●●●●● ●●●●●●
Trevi Therapeutics will present quality-of-life data from its clinical trials for its chronic cough treatment candidate at the upcoming ERS Congress. This presentation serves to share existing clinical findings with the medical community and has no immediate impact on the stock price.…more
$12.43-1.35%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report